Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
IDE397 (GSK-4362676) | MAT2A Inhibitor | CAS 2439277-80-0 | Selleck ...
IDE397 (MAT2A inhibitor) - Molecular Sherlock
IDE397 (GSK-4362676; MAT2A-IN-9) | CAS 2439277-80-0 | AbMole BioScience ...
IDEAYA Announces Phase 1/2 Expansion for IDE397 and Trodelvy ...
Paolo Tarantino: Intersecting data with the MAT2A inhibitor IDE397 in ...
Ide397 – Application in Therapy and Current Clinical Research
IDE397 | 2439277-80-0 | AbMole | GSK-4362676; MAT2A-IN-9
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion ...
(PDF) 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A ...
Ideaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397 ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a ...
AMG 193 + IDE397 for Solid Cancers Clinical Trial 2024 | Power
IDE397 + Trodelvy Combo in MTAP-Deletion Cancers: A Precision Oncology ...
BYUNGJUNE PARK on LinkedIn: IDEAYA Biosciences' IDE397 has shown ...
AMG 193 + IDE397 for Solid Cancers Clinical Trial 2025 | Power
Study of AMG 193 and IDE397 for Adults with Advanced MTAP-null Solid ...
IDE397 shows promise in MTAP-deletion urothelial carcinoma
IDEAYA Biosciences (NASDAQ:IDYA) shows strong phase 2 IDE397 results
Schematic representation of the three-dimensional structure of the ...
IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success ...
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular ...
IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial ...
Methionine Lewis Structure
D-Day For IDEAYA - IDE397 Data To Be Unveiled Tomorrow
The Insulin-Degrading Enzyme from Structure to Allosteric Modulation ...
Nucleotide Analog ARL67156 as a Lead Structure for the Development of ...
Structure of indoles Org27569 (pharmacological profile in Table 1 ...
Slide 13
Slide 12
Slide 16
Slide 11
首创MAT2A抑制剂IDE397治疗MTAP缺失的晚期尿路上皮癌和非小细胞肺癌，疾病控制率93%！ - 知乎
MAT2A-IN-9 | Methionine Adenosyltransferase (MAT) | TargetMol
Abstract 1278: MAT2A inhibitor, IDE397, displays broad anti-tumor ...
研究性MAT2A抑制剂IDE397早期临床结果积极，超90%晚期癌症患者疾病得到控制-上市-医保-临床适应症-香港济民药业
Abstract B027: The MAT2A inhibitor IDE397: a novel combination backbone ...
IDE-397(IDE-397) - 药物靶点：Mat2A_在研适应症：非小细胞肺癌，甲硫腺苷磷酸化酶缺失实体瘤，尿路上皮癌_专利_临床_研发
LOGO
Positive Interim Phase II Data Show Strong Overall Response and Disease ...
IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of ...
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination ...
IDE397: a novel MAT2A inhibitor in patients with solid tumors harboring ...
IDEAYA与安进达成临床试验合作，评估MAT2A-PRMT5 合成致死组合
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data ...
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating ...
AGI-24512 | MAT2A inhibitor | CAS 2201066-53-5 | Selleck
AG-270 | MAT2A inhibitor | CAS 2201056-66-6 | Selleck
Drug combination screens uncover synergistic interactions between ...
Slide 5
MAT2A抑制剂专利突破案例-英矽智能 - 知闻 ZHI WEN
MRTX-1719: Overview, Applications as Antitumor Agents and its Dynamic ...
Exploring the Structural Rearrangements of the Human Insulin-Degrading ...
Slide 17
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 ...
Slide 3
IDE-397(IDE-397) - 药物靶点：Mat2A_在研适应症：食管癌，非小细胞肺癌，甲硫腺苷磷酸化酶缺失实体瘤_专利_临床_研发
Combined pembrolizumab and bevacizumab therapy effectively inhibits non ...
New Horizons of Synthetic Lethality in Cancer: Current Development and ...
Slide 14
IDEAYA announces further Gilead sciences clinical study collaboration ...
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality ...
Design and rationale of tetrasubstituted imidazole derivatives The ...
IDEAYA initiates subject dosing in Phase I bladder cancer trial
IDE397联合Trodelvy：MTAP缺失尿路上皮癌治疗新希望，临床研究揭示积极疗效 - MedFind
A small molecule inhibitor 1,2,4,5-Benzenetetraamine tetrahydrochloride ...
CID 49799987 | C27H31I6N3O11 | CID 49799987 - PubChem
modification | IDT
Ribbons representation of the IDE crystal structure. The position of ...
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for ...
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus ...
合成致死领域药物研发现状医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Synthesis and Biological Evaluation of Novel Synthetic Indolone ...
BeiGene is next into MAT2A inhibition | ApexOnco - Clinical Trials news ...
Structures of and common names for insulin-degrading enzyme (IDE ...
The structures of 1 (E-837), 2 (E-492) and 3 (E-975). | Download ...
398507-63-6 | CAS DataBase
This table represents the structures, ids, and names of the initially ...
Imidazoles as Serotonin Receptor Modulators for Treatment of Depression ...
有效率100%！美国新药IDE397联合Trodelvy，为MTAP缺失型尿路上皮癌患者带来新希望-出国看病-盛诺一家
IDEAYA reports positive data from Phase II cancer therapy trial
US10793576, Example 39 | C28H25N7O3 | CID 146177010 - PubChem
Exclusive Solvent-Controlled Regioselective Catalytic Synthesis of ...
IDE1 | STEMCELL Technologies
(IUCr) Synthesis of 5-(arylmethylideneamino)-4-(1 H -benzo[ d ...
Miscellaneous imidazole base structures [22, 27, 52-53]. | Download ...
